VEGFA and neoplasm: As a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) can block VEGF signal transduction to generate an anti-tumor effect by inhibiting neovascularization and suppressing edema11,12, but as a result, BEV can also increase tumor cell invasion in GBM13.